BIO89-100

DRUG2 trials

Sponsors

89bio, Inc.

Conditions

NASH - Nonalcoholic Steatohepatitis

Phase 1

PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

CompletedNCT05022693

89bio, Inc.NASH - Nonalcoholic Steatohepatitis

Start: 2021-08-16End: 2021-12-21Updated: 2022-03-02

Phase 2

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

CompletedNCT04929483

89bio, Inc.NASH - Nonalcoholic Steatohepatitis

Start: 2021-06-04End: 2024-10-08Updated: 2026-01-06

Related Papers

Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

Clinical Pharmacology & Therapeutics2023-09-123 citations

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

New England Journal of Medicine2023-06-24372 citations